Product Name:
B-Raf-pS729
Product Number:
ab-pk536
Target Full Name: B-Raf proto-oncogene serine-threonine-protein kinase; RafB proto-oncogene-encoded protein-serine kinase
Target Alias: B-RAF; B-RAF proto-oncogene serine/threonine-protein kinase; BRAF1; C-RMIL; Kinase B-Raf; P94; RAFB1; RMIL; RMIL serine/threonine-protein kinase; V-Raf murine sarcoma viral oncogene homolog B1; MGC126806; MGC138284; CCDS5863.1; ENSG00000157764
Product Type Specific: Protein kinase phosphosite-specific antibody
Antibody Code: PK535
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: S729
Protein UniProt: P15056
Protein SigNET: P15056
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human Raf-B (BRaf) sequence peptide Cat. No.: PE-04AEA99
Antibody Immunogen Sequence: RSA(pS)EPS(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues R726 to S732; In the C-terminal region after the kinase catalytic domain.
Production Method: Corresponds to amino acid residues R726 to S732; In the C-terminal region after the kinase catalytic domain.
Antibody Modification: Protein kinase phosphosite-specific antibody
Antibody Concentration: 0.3 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Medium-weak immunoreactivity of a target-sized protein by Western blotting in HEK-293 cells. Strong immunoreactivity with immunogen peptide on dot blots. Very strong immunoreactivity with recombinant human B-Raf on protein dot blots.
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 87-97 kDa.
Antibody Specificity: Very high
Antibody Cross Reactivity: Strong immunoreactivity on protein dot blots with recombinant human Raf1, which features an identical phosphosite sequence. Cross-reacts with CDK1 and a 25 kDa protein in sea star oocytes, and a 27 kDa protein in HEK-293 cells.
Related Product 1: B-Raf-pS729 blocking peptide
Related Product 2: B-Raf-pS446+pS447 phosphosite-specific antibody (Cat. No.: AB-PK534)
Related Product 3: B-Raf-2 pan-specific antibody (Cat. No.: AB-NK156-6)
Related Product 4: BRaf-3 pan-specific antibody (Cat. No.: AB-NK156-4)
Related Product 5: RafB-CT (RafB-4) pan-specific antibody (Cat. No.: AB-NK156-2)
Related Product 6: B-Raf pan-specific antibody (Cat. No.: AB-NK156-3)
Related Product 7: B-Raf pan-specific antibody (Cat. No.: AB-NK156-4P)
Scientific Background: B-Raf (RAFB1) is a protein-serine/threonine kinase of the TKL group and RAF family. It is a cytoplasmic kinase that participates in the RAS>RAF>MEK>ERK pathways, which is involved in the transduction of mitogenic signals from the cell membrane to the nucleus and promotion of cell division, differentiation, and cytokine secretion. Ras isoforms are inactive when bound to GDP, but when they are bound to GTP they become active and promote stimulation of B-Raf. Phosphorylation of S446 increases phosphotransferase activity and induces interaction with H-Ras-1. Phosphorylation of S579, T599, and S602 increases B-Raf phosphotransferase activity. Phosphorylation of S729 increases phosphotransferase activity and induces interaction with 14-3-3 beta. Phosphorylation of S365, S429, and T440 inhibits phosphotransferase activity. Phosphorylation of T753 inhibits interaction with Raf1. B-Raf is expressed in most tissues with high expression in neuronal tissue. The transcription of several genes have been found to be increased by this pathway, including cyclins D1, D2 and D3, VEGF, c-myc, b3-integrin and mdm2. B-RAF is a known oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. Gain-of-function mutations in B-Raf are estimated to be present in ~15-19% of all human cancers, and 66% of malignant melanomas have been identified with a B-Raf somatic missense mutation. A single point mutation (V600E), located in the kinase catalytic domain in the activation loop between Subdomains VII and VIII. It has been reported to account for ~80% of the B-Raf mutations in human cancers. Mutated B-Raf proteins display constitutive elevated levels of phosphotransferase activity, resulting in the aberrant promotion of cell division, differentiation, and cytokine secretion.
